246 related articles for article (PubMed ID: 24505826)
1. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
von Tigerstrom B
Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
[TBL] [Abstract][Full Text] [Related]
2. FDA challenges stem-cell clinic.
Cyranoski D
Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
[No Abstract] [Full Text] [Related]
3. FDA's claims over stem cells upheld.
Cyranoski D
Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
[No Abstract] [Full Text] [Related]
4. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
Knoepfler PS
Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
[TBL] [Abstract][Full Text] [Related]
5. Rejuvenating Regenerative Medicine Regulation.
Charo RA; Sipp D
N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
[No Abstract] [Full Text] [Related]
6. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States.
Lee MH; Arcidiacono JA; Bilek AM; Wille JJ; Hamill CA; Wonnacott KM; Wells MA; Oh SS
Tissue Eng Part B Rev; 2010 Feb; 16(1):41-54. PubMed ID: 19728784
[TBL] [Abstract][Full Text] [Related]
7. Allowing innovative stem cell-based therapies outside of clinical trials: ethical and policy challenges.
Hyun I
J Law Med Ethics; 2010; 38(2):277-85. PubMed ID: 20579251
[TBL] [Abstract][Full Text] [Related]
8. A RAT by Another Name: 21
Riley MF
Am J Law Med; 2018 May; 44(2-3):291-308. PubMed ID: 30106653
[No Abstract] [Full Text] [Related]
9. FDA regulation of adult stem cell therapies as used in sports medicine.
Chirba MA; Sweetapple B; Hannon CP; Anderson JA
J Knee Surg; 2015 Feb; 28(1):55-62. PubMed ID: 25603042
[TBL] [Abstract][Full Text] [Related]
10. Federal Regulatory Oversight of US Clinics Marketing Adipose-Derived Autologous Stem Cell Interventions: Insights From 3 New FDA Draft Guidance Documents.
Turner LG
Mayo Clin Proc; 2015 May; 90(5):567-71. PubMed ID: 25939934
[No Abstract] [Full Text] [Related]
11. Texas H.B. 810: Increased Access to Stem Cell Interventions or an Increase in Unproven Treatments?
Matthews K; Kunisetty B; Sprung K
Stem Cells Dev; 2018 Nov; 27(21):1463-1465. PubMed ID: 30122128
[TBL] [Abstract][Full Text] [Related]
12. Regulating autologous adult stem cells: the FDA steps up.
Lysaght T; Campbell AV
Cell Stem Cell; 2011 Nov; 9(5):393-6. PubMed ID: 22056136
[TBL] [Abstract][Full Text] [Related]
13. US FDA outreach to the regenerative medicine community: challenges and opportunities.
Whittlesey KJ; Witten C
Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
[TBL] [Abstract][Full Text] [Related]
14. FDA regulation of stem-cell-based therapies.
Halme DG; Kessler DA
N Engl J Med; 2006 Oct; 355(16):1730-5. PubMed ID: 17050899
[No Abstract] [Full Text] [Related]
15. Regulatory crackdown on stem cell therapy: what would the position be in South Africa?
Jordaan D
S Afr Med J; 2012 Mar; 102(4):219-20. PubMed ID: 22464500
[TBL] [Abstract][Full Text] [Related]
16. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
Sipp D
Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
[TBL] [Abstract][Full Text] [Related]
17. New Japanese initiatives on stem cell therapies.
Konomi K; Tobita M; Kimura K; Sato D
Cell Stem Cell; 2015 Apr; 16(4):350-2. PubMed ID: 25842974
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the FDA regenerative medicine framework: opportunities for stakeholders.
Richardson E; Akkas F; Master Z
Regen Med; 2020 Jul; 15(7):1825-1832. PubMed ID: 32815780
[No Abstract] [Full Text] [Related]
19. Regulation of Regenerative Medicine Products.
Gee AP
Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
[TBL] [Abstract][Full Text] [Related]
20. Adult stem cell therapies walk the line.
DeFrancesco L
Nat Biotechnol; 2012 Aug; 30(8):739-41. PubMed ID: 22871705
[No Abstract] [Full Text] [Related]
[Next] [New Search]
